New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
18:43 EDTARNA, GSK, RHHBYGlaxoSmithKline interested in Arena, Daily Mail says
GlaxoSmithKline (GSK) may be interested in a bid for Arena Pharmaceuticals (ARNA), and if GSK makes a move for Arena, Roche (RHHBY) could get involved too, reports the U.K.'s Daily Mail. Shares of Arena are up 2.2% to $7.35 in after hours trade. Reference Link
News For ARNA;GSK;RHHBY From The Last 14 Days
Check below for free stories on ARNA;GSK;RHHBY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 22, 2014
07:21 EDTGSKEBD Group to hold a conference
Subscribe for More Information
05:27 EDTGSKGlaxoSmithKline upgraded to Buy from Neutral at Goldman
Subscribe for More Information
September 20, 2014
15:43 EDTRHHBYInterMune reports MOU in connection with consolidated Delaware action
Subscribe for More Information
September 19, 2014
05:58 EDTGSKGlaxoSmithKline to pay GBP 297M fine to Chinese government
Subscribe for More Information
September 17, 2014
14:57 EDTGSKProsensa announces commencement of re-dosing of drisapersen
Subscribe for More Information
11:00 EDTRHHBYRoche CEO rules out megadeals, focused on bolt-on acquisitions, WSJ says
Roche CEO Severin Schwan said the company won't change its acquisition strategy following the recent deals made or abandoned in the pharmaceutical sector, reports the Wall Street Journal. In an interview with WSJ, Shwan said, "We have been very consistent in our approach to M&A." Regarding transformational deal-making, he said, "We have no intention to do that, whatever happens in the industry." Reference Link
07:43 EDTRHHBY, ARNABofA/Merrill to hold a conference
Subscribe for More Information
07:39 EDTGSKMorningstar to hold a conference
Management Behind the Moat Conference to be held in Chicago on September 17-18.
September 16, 2014
09:59 EDTARNAArena to need longer studies of 'Bel-phen' combo to judge safety, TheStreet says
Subscribe for More Information
07:33 EDTGSKMylan initiates Phase III clinical trials for Advair Diskus and Lantus
Mylan (MYL) announced it is initiating Phase III clinical trials for its generic version of GlaxoSmithKline's (GKS) Advair Diskus and its insulin analog to Sanofi's (SNY) Lantus. In October Mylan will commence a Phase III clinical trial to evaluate the equivalence of its product to Advair Diskus when administered by inhalation in adult asthma patients.
07:31 EDTGSK, RHHBYEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 15, 2014
16:10 EDTGSKFive Prime announces option exercise by GlaxoSmithKline to obtain license
Subscribe for More Information
07:27 EDTGSKIBC Life Sciences to hold a conference
Subscribe for More Information
September 11, 2014
12:42 EDTARNAOrexigen falls after FDA requires warnings on Contrave label
Subscribe for More Information
10:59 EDTARNAArena competition picks up after Contrave approval, says Piper Jaffray
Subscribe for More Information
08:01 EDTARNAOrexigen Contrave could have stronger launch than peers, says Wells Fargo
After the FDA approved Orexigen's (OREX) Contrave as a treatment option for chronic weight management, Wells Fargo does not believe the label included any significant surprises. The firm thinks multiple factors increase the chances that Contrave's launch will be stronger than two other weight loss drugs that were launched in recent years by VIVUS and Arena Pharmaceuticals (ARNA). The firm keeps an Outperform rating on Orexigen.
September 10, 2014
13:04 EDTRHHBYRoche unit receives orphan status for lung cancer mutation drug
Subscribe for More Information
09:58 EDTGSKGlaxoSmithKline has a conference call hosted by JPMorgan
Subscribe for More Information
September 9, 2014
12:46 EDTARNANovo Nordisk weight loss drug helped people get thinner, Bloomberg reports
Subscribe for More Information
06:25 EDTGSKDocuments show DOJ probed GSK China unit in 2012, Reuters says
Internal documents revealed that a U.S. anti-bribery investigation into GlaxoSmithKline (GSK) touched on the firm's Chinese consumer healthcare division two years ago, which infers that the company's compliance issues in the country could be broader than initially discovered, according to Reuters, citing the documents. Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use